This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Jentadueto

Boehringer Ingelheim GmbH

Drug Names(s): linagliptin (Ondero)/metformin fixed dose combination (FDC), Jentadueto XR

Description: Linagliptin is a novel, selective, and long acting DPP-IV inhibitor. Inhibition of DPP4 increases the amount of circulating active GLP-1, a peptide that increases insulin secretion in a glucose-dependent fashion, thereby lowering blood glucose levels.

Metformin is a biguanide that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Though not definitively established, recent evidence suggests its intracellular target is AMP-activated protein kinase, which regulates lipid and glucose metabolism.

Deal Structure: Historical revenues for Jentradueto are recorded under Tradjenta.

In January 2011, Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim's two oral diabetes agentslinagliptin and BI10773as well as Lilly's two basal insulin analoguesLY2605541 and LY2963016as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody.

Under the terms of the agreement, Lilly will make an initial one-time payment to Boehringer Ingelheim of euro 300 million. Boehringer Ingelheim will be eligible to receive up to a total of euro 625 million in success-based regulatory milestones for linagliptin and BI10773. Lilly will be eligible to receive up to a total of $650 million in success-based regulatory milestones on its two basal analogue...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company


Jentadueto News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug